Read the whole press release at: http://www.biovitrum.com/templates/InformationPage.aspx?id=818 For further information, please contact: Biovitrum AB (publ) Martin Nicklasson, CEO Phone: +46 8 697 20 00 Göran Arvidson, CFO Phone: +46 70 633 30 42 Erik Kinnman, VP Investor Relations Phone: +46 73 422 15 40 [email protected] About Biovitrum Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the Transaction). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com. The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 8:00 CET on December 2nd, 2009.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.